Articles Tagged With:
-
Leading the Charge in 2021: Managing Capacity
Approaching one year after COVID-19 began spreading in the United States, case managers are considering how to make the most of their new perspective in 2021 and beyond. The pandemic has shone a light on case management program and healthcare facility weaknesses, but also has brought new opportunities for leadership and advocacy. What can case managers do to maximize these opportunities and avoid pitfalls?
-
Accreditation Program Elevates Pain and Addiction Care in the ED
Long before the COVID-19 pandemic, frontline providers were confronting an epidemic of patients struggling with opioid use disorders (OUD). Recognizing the urgent need for improvement in this area, the American College of Emergency Physicians is rolling out a new accreditation program that is aimed at nudging EDs across the country to up their game when it comes to both the treatment of pain and the way they manage patients who present with OUD.
-
Try Using Telehealth to Diagnose and Manage Patients with Dizziness
Appreciating the need for more guidance in this area, an international task force comprised of physician-scientists from 10 countries developed consensus-based guidelines to help frontline providers diagnose and triage patients with dizziness over a telehealth or virtual platform.
-
Researchers Study the Effects of Intensive Primary Care
A case management-type of model, called primary care intensive management, could provide some limited benefits for more complex patients, research shows. But the research also suggests questions about how population health resources are best spent.
-
Follow-Up Is Crucial but Difficult for Case Managers During Pandemic
The pandemic exacerbated social determinants of health problems for many patients seen by case managers. Case managers had to find new resources for patients, including aid from the CARES Act.
-
As Pandemic Rages, Case Managers Can Focus on Crisis Management
Crisis management is important to case management leaders and their teams as the COVID-19 pandemic continues. COVID-19 cases and hospitalizations sharply increased through the end of 2020.
-
FDA Issues Third COVID-19 Therapeutic EUA This Month
The list of COVID-19 therapeutics is growing rapidly.
-
Nutritional Interventions in Prodromal Alzheimer’s Disease: The 36-Month LipiDiDiet Multinutrient Clinical Trial
In a randomized, double-blind, placebo-controlled trial of Fortasyn Connect (Souvenaid), a nutraceutical drink, patients with prodromal Alzheimer’s disease demonstrated, over a 36-month period, a slower decline in cognitive functions compared to the control group.
-
Disease-Modifying Therapy and Long-Term Disability in Multiple Sclerosis
In a multicenter, observational, retrospective “real world” analysis of a large cohort of relapsing multiple sclerosis (MS) patients, the authors found that being on disease-modifying therapy decreased the risk of long-term disability progression in both pediatric and adult MS patients.
-
Multiple Sclerosis and Vascular Disease
This postmortem study of multiple sclerosis (MS) patients evaluated the presence and pathological significance of extracranial systemic and cerebral small vessel disease in patients with MS compared to healthy controls. MS patients had less systemic vascular disease and more small vessel disease in the brain compared to controls.